Results 31 to 40 of about 12,775 (197)
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang +15 more
wiley +1 more source
A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. [PDF]
PLoS ONE, 2013 PurposeTo assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT).MethodsThe sample size of this ...
Simone Cesaro +6 more
doaj +1 more source
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]
, 2013 BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du +13 more
core +1 more source
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed +6 more
wiley +1 more source
Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis [PDF]
, 2004 1427 E 60TH ST, CHICAGO, USA, IL, 60637 ...
Allen C. Cheng +16 more
core +1 more source
European Journal of Haematology, Volume 116, Issue 5, Page 604-614, May 2026.ABSTRACT Introduction Cryopreservation of peripheral‐blood‐derived hematopoietic stem and progenitor cells (PBSCs) has been used for decades, primarily for autologous transplantation. Now, in the era of new cellular therapies, the cryopreservation of allogeneic PBSCs may also become relevant.
Philipp Blüm +5 more
wiley +1 more source
BMC Cancer, 2008 Background Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in ...
Noga Stephen J +9 more
doaj +1 more source
Emergence of the Biosimilar Sector and Opportunities of Developing Country Suppliers [PDF]
, 2011 As biologic products begin to come off-patent, a market is emerging for biosimilars (also known as biogenerics or follow-on biologics). Firms from emerging countries such as India and China have dominated the production of active ingredients in ...
Huzair, Farah, Kale, Dinar
core
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
ClinicoEconomics and Outcomes Research, 2018 Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS +6 more
doaj